FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2736971732> ?p ?o ?g. }

• W2736971732 endingPage "5472" @default.
• W2736971732 startingPage "5472" @default.
• W2736971732 abstract "Abstract Background: the Registro Italiano Trombocitemie (RIT) was activated mainly to evaluate the diagnosis and therapy appropriateness in the thrombocythemic patients with Ph-negative myeloproliferative neoplasm (MPN) observed in the adhering centers. Objective: to evaluate how the diagnostic and therapeutic approach changed in the RIT patients diagnosed with thrombocythemic MPN in the last two decades. Methods: the RIT centers registered by a web-based system during the years 2005-2014 their thrombocythemic MPN patients, and semesterly updated their follow-up data. For patients diagnosed before 2005, the data on diagnosis and prior follow-up were retrospectively collected. The diagnostic process and the initial treatment (started into the first year after diagnosis) were comparatively analyzed in the patients diagnosed before and after 2005. Results: the RIT centers registered 2629 patients. 2388 of them, object of this analysis, were diagnosed between1995 and 2014: 1098 (46%) in the decade 1995-2004 (Group I), and 1290 (54%) in the decade 2005-2014 (Group II). The diagnostic process in the patients of Group II and Group I included bone marrow biopsy (BMB, performed into 1 year and before any cytoreduction): 85% vs 80%, p <0.001; clonality tests (JAK2 and/or others): 80% vs 9%, p<0.001; cytogenetic evaluation: 55% vs 57%, p 0.58; abdominal echography: 46% vs 41%, p 0.016. The patients of Group II, as compared with those of Group I, showed a similar gender distribution (M/F ratio 0.61 vs 0.65, p 0.452), and had at diagnosis: a higher age (median 60 vs 57 years, p <0.001; age >60 years in 50% vs 45% of cases, p <0.01); a similar rate of prior thrombosis (19% vs 19%), prior hemorrhage (3% vs 4%), CVRFs 69% vs 66%), splenomegaly (25% vs 25%), and hepatomegaly (22% vs 24%); a lower rate of disease-related symptoms (36% vs 40%, p 0.04); a higher rate of comorbidities (55% vs 51%, p 0.03). Moreover, they had: a lower platelet (PLT) count (median 737 vs 775 x 109/L, p <0.001; <600 x 109/L in 22% vs 14% of cases, p <0.001); a similar white blood cell (WBC) count (median 8.6 vs 8.5 x 109/L; >10 x 109/L in 28% vs 26% cases); a similar median levels of hematocrit (HCT %, in females 41.4 vs 41.0; in males 44.7 vs 44.6) and hemoglobin (Hb g/dL, in females 13.8 vs 13.6; in males 15.0 vs 14.9). The BMB, revised according to the WHO 2008 criteria, showed a not different distribution (p 0.21) of ET (64% vs 61%), ep-PMF (16% vs 17%), PMF (3% vs 2%), PV (4% vs 4%), and U-MPN (13% vs 16%. The JAK2 V617F mutation in patients of Group II (at diagnosis) and of Group I (after diagnosis) was found in 62% and in 58% of tested cases (p 0.054), respectively. The patients at high standard thrombotic risk were 58% vs 52%, p 0.004. In the patients of Group II and Group I the distribution of the treatment started into the first year was significantly different (p<0.001): AntiPLT 29% vs 24%, CYT 13% vs 16%, CYT+AntiPLT 49% vs 46%, CYT ± AntiPLT 62% vs 62%, AntiPLT ± CYT 78% vs 69%. The treatment CYT ± AntiPLT was started in the patients at high standard thrombotic risk with a rate of 81% vs 80%, respectively, and in the patients at low standard thrombotic risk in 37% vs 43% of cases, respectively. The initial treatment CYT±AntiPLT was related, in multivariate analysis, both in patients of Group II and Group I, with older age (>60 and 40-60 vs <40 years, p <0.001), higher PLT count (>1000 and 700-1000 vs <700 x 109/L, p <0.001), prior thrombosis (p <0.001), symptoms (p <0.001). Noteworthy, no relationship was found with JAK2 mutation, and WHO diagnosis. Conclusion: in the studied thrombocythemic MPN patients the real-life diagnostic approach was improved after 2005 not only due to the routine use of JAK2 tests, but also due to the higher rate of BMB done (85% vs 80%). The appropriateness of the cytoreductive treatment (CYT±AntiPLT started into one year from diagnosis) remained high in patients at high standard thrombotic risk (over 80% of cases were treated). Concomitantly, the inappropriate use of the cytoreductive drugs in patients at low standard thrombotic risk appreciably decreased (from 43% to 37% of cases). Moreover, it has to be remarked that the therapeutic approach was significantly influenced not only by older age and prior thrombosis, but also by thrombocytosis (PLT count >700 x 109/L), disease-related symptoms, and inconstantly by leukocytosis and CVRFs. Table Table. Disclosures Gugliotta: SHIRE Co.: Honoraria. Gugliotta:Bristol Myers Squibb: Consultancy, Honoraria; Novartis: Consultancy, Honoraria." @default.
• W2736971732 created "2017-07-31" @default.
• W2736971732 creator A5002114072 @default.
• W2736971732 creator A5003619706 @default.
• W2736971732 creator A5006463286 @default.
• W2736971732 creator A5006810419 @default.
• W2736971732 creator A5008040655 @default.
• W2736971732 creator A5008566093 @default.
• W2736971732 creator A5013237232 @default.
• W2736971732 creator A5015829148 @default.
• W2736971732 creator A5017819710 @default.
• W2736971732 creator A5018412128 @default.
• W2736971732 creator A5019087367 @default.
• W2736971732 creator A5019630321 @default.
• W2736971732 creator A5019993467 @default.
• W2736971732 creator A5024930687 @default.
• W2736971732 creator A5029714829 @default.
• W2736971732 creator A5035304659 @default.
• W2736971732 creator A5035566807 @default.
• W2736971732 creator A5036361364 @default.
• W2736971732 creator A5042860573 @default.
• W2736971732 creator A5045651843 @default.
• W2736971732 creator A5046772202 @default.
• W2736971732 creator A5047421266 @default.
• W2736971732 creator A5051228886 @default.
• W2736971732 creator A5051527815 @default.
• W2736971732 creator A5051915793 @default.
• W2736971732 creator A5054685615 @default.
• W2736971732 creator A5056029238 @default.
• W2736971732 creator A5056625326 @default.
• W2736971732 creator A5057705097 @default.
• W2736971732 creator A5061176005 @default.
• W2736971732 creator A5061602224 @default.
• W2736971732 creator A5061865843 @default.
• W2736971732 creator A5063271841 @default.
• W2736971732 creator A5063478076 @default.
• W2736971732 creator A5063836948 @default.
• W2736971732 creator A5065918826 @default.
• W2736971732 creator A5066768069 @default.
• W2736971732 creator A5068891934 @default.
• W2736971732 creator A5071466957 @default.
• W2736971732 creator A5072484806 @default.
• W2736971732 creator A5074396899 @default.
• W2736971732 creator A5077510334 @default.
• W2736971732 creator A5078392742 @default.
• W2736971732 creator A5080563685 @default.
• W2736971732 creator A5080840329 @default.
• W2736971732 creator A5083927794 @default.
• W2736971732 creator A5084906998 @default.
• W2736971732 creator A5085459773 @default.
• W2736971732 creator A5086845182 @default.
• W2736971732 creator A5087305075 @default.
• W2736971732 creator A5088538033 @default.
• W2736971732 creator A5090137004 @default.
• W2736971732 date "2016-12-02" @default.
• W2736971732 modified "2023-09-26" @default.
• W2736971732 title "How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT)" @default.
• W2736971732 doi "https://doi.org/10.1182/blood.v128.22.5472.5472" @default.
• W2736971732 hasPublicationYear "2016" @default.
• W2736971732 type Work @default.
• W2736971732 sameAs 2736971732 @default.
• W2736971732 citedByCount "0" @default.
• W2736971732 crossrefType "journal-article" @default.
• W2736971732 hasAuthorship W2736971732A5002114072 @default.
• W2736971732 hasAuthorship W2736971732A5003619706 @default.
• W2736971732 hasAuthorship W2736971732A5006463286 @default.
• W2736971732 hasAuthorship W2736971732A5006810419 @default.
• W2736971732 hasAuthorship W2736971732A5008040655 @default.
• W2736971732 hasAuthorship W2736971732A5008566093 @default.
• W2736971732 hasAuthorship W2736971732A5013237232 @default.
• W2736971732 hasAuthorship W2736971732A5015829148 @default.
• W2736971732 hasAuthorship W2736971732A5017819710 @default.
• W2736971732 hasAuthorship W2736971732A5018412128 @default.
• W2736971732 hasAuthorship W2736971732A5019087367 @default.
• W2736971732 hasAuthorship W2736971732A5019630321 @default.
• W2736971732 hasAuthorship W2736971732A5019993467 @default.
• W2736971732 hasAuthorship W2736971732A5024930687 @default.
• W2736971732 hasAuthorship W2736971732A5029714829 @default.
• W2736971732 hasAuthorship W2736971732A5035304659 @default.
• W2736971732 hasAuthorship W2736971732A5035566807 @default.
• W2736971732 hasAuthorship W2736971732A5036361364 @default.
• W2736971732 hasAuthorship W2736971732A5042860573 @default.
• W2736971732 hasAuthorship W2736971732A5045651843 @default.
• W2736971732 hasAuthorship W2736971732A5046772202 @default.
• W2736971732 hasAuthorship W2736971732A5047421266 @default.
• W2736971732 hasAuthorship W2736971732A5051228886 @default.
• W2736971732 hasAuthorship W2736971732A5051527815 @default.
• W2736971732 hasAuthorship W2736971732A5051915793 @default.
• W2736971732 hasAuthorship W2736971732A5054685615 @default.
• W2736971732 hasAuthorship W2736971732A5056029238 @default.
• W2736971732 hasAuthorship W2736971732A5056625326 @default.
• W2736971732 hasAuthorship W2736971732A5057705097 @default.
• W2736971732 hasAuthorship W2736971732A5061176005 @default.
• W2736971732 hasAuthorship W2736971732A5061602224 @default.
• W2736971732 hasAuthorship W2736971732A5061865843 @default.
• W2736971732 hasAuthorship W2736971732A5063271841 @default.
• W2736971732 hasAuthorship W2736971732A5063478076 @default.
• W2736971732 hasAuthorship W2736971732A5063836948 @default.

• next